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Strengths and limitations of this study
 ► This will be the first large-series, geographically 
comprehensive, multicentre, international, pro-
spective cohort study to define the management 
and outcomes of a selection of common congenital 
anomalies in low, middle and high income countries 
across the globe.
 ► The collaborative approach for this study allows a 
large series of high-quality data to be collected in a 
timely manner without overburdening high-volume, 
low-resource centres.
 ► The seven study conditions constitute a selection of 
the most common life-threatening congenital anom-
alies requiring emergency surgical care in the neo-
natal period (box 1).
 ► We recognise that some children may not reach a 
facility capable of providing acute paediatric surgi-
cal care and hence the results obtained may be an 
underestimation of true morbidity and mortality, es-
pecially in low and middle income countries.
 ► The number of variables being collected per patient 
has been limited to those known to have the great-
est impact on outcomes to optimise the feasibility of 
the study; follow-up is limited to 30 days post-pri-
mary intervention.
ABSTRACT
Introduction Congenital anomalies are the fifth leading 
cause of death in children <5 years of age globally, 
contributing an estimated half a million deaths per year. 
Very limited literature exists from low and middle income 
countries (LMICs) where most of these deaths occur. The 
Global PaedSurg Research Collaboration aims to undertake 
the first multicentre, international, prospective cohort study 
of a selection of common congenital anomalies comparing 
management and outcomes between low, middle and high 
income countries (HICs) globally.
Methods and analysis The Global PaedSurg Research 
Collaboration consists of surgeons, paediatricians, 
anaesthetists and allied healthcare professionals involved 
in the surgical care of children globally. Collaborators will 
prospectively collect observational data on consecutive 
patients presenting for the first time, with one of seven 
common congenital anomalies (oesophageal atresia, 
congenital diaphragmatic hernia, intestinal atresia, 
gastroschisis, exomphalos, anorectal malformation and 
Hirschsprung's disease).
Patient recruitment will be for a minimum of 1 month 
from October 2018 to April 2019 with a 30-day post-
primary intervention follow-up period. Anonymous data 
will be collected on patient demographics, clinical status, 
interventions and outcomes using REDCap. Collaborators 
will complete a survey regarding the resources and 
facilities for neonatal and paediatric surgery at their 
centre.
The primary outcome is all-cause in-hospital mortality. 
Secondary outcomes include the occurrence of post-
operative complications. Chi-squared analysis will be used 
to compare mortality between LMICs and HICs. Multilevel, 
multivariate logistic regression analysis will be undertaken 
to identify patient-level and hospital-level factors affecting 
outcomes with adjustment for confounding factors.
Ethics and dissemination At the host centre, this study 
is classified as an audit not requiring ethical approval. 
All participating collaborators have gained local approval 
in accordance with their institutional ethical regulations. 
Collaborators will be encouraged to present the results 
locally, nationally and internationally. The results will be 
submitted for open access publication in a peer reviewed 
journal.
Trial registration number NCT03666767
InTRoduCTIon
In 2015, the Global Burden of Disease study 
concluded congenital anomalies (also known 
as congenital malformations, congenital 
abnormalities or birth defects) to be the fifth 
leading cause of death in children <5 years of 
age globally.1 This equates to approximately 
half a million deaths from congenital anoma-
lies each year, 97% of which occur in low and 
middle income countries (LMICs). Indeed, 
this is likely to be an underestimation of the 
actual number of deaths due to underdiag-
nosis of neonates with congenital anomalies 
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Box 1 Congenital anomalies in the Global PaedSurg Study
 ► Oesophageal atresia ± tracheo-oesophageal fistula
 ► Congenital diaphragmatic hernia
 ► Intestinal atresia
 ► Gastroschisis
 ► Exomphalos
 ► Anorectal malformation
 ► Hirschsprung’s disease
who die in the community and a lack of death certi-
fication in many LMICs.2 Not only is the mortality rate 
higher in LMICs, but the prevalence is also higher due 
to micronutrient deficiencies, infections and teratogens 
during pregnancy resulting in more cases and a lack of 
antenatal diagnosis prohibiting terminations.3 4 There is 
limited research and a lack of congenital anomaly regis-
tries in LMICs, and hence they have received very little 
global attention.5
The conditions forming the focus of this study (box 1) 
constitute a selection of the most common life-threat-
ening congenital anomalies during the neonatal period, 
which involve the gastrointestinal tract. They each have 
an incidence of 1/2000 to 1/5000, they collectively form 
up to 40% of emergency neonatal surgery and associ-
ated mortality can be in excess of 50% in many LMICs.6–9 
Disparities in outcomes globally can be stark; for example, 
the mortality from gastroschisis is 75%–100% in many 
LMICs compared with 4% or less in high income coun-
tries (HICs).10–12 Reasons for poor outcomes include a 
lack of antenatal diagnosis, delayed presentation, limited 
neonatal transport and in-hospital resources, a dearth of 
trained support personnel and a lack of intensive care 
and parenteral nutrition for neonates.9 13 14 In Uganda, 
it was calculated that only 3.5% of the need for neonatal 
surgery was met by the healthcare system.8
In 2010, the World Health Assembly passed a resolu-
tion recommending ‘prevention whenever possible, to 
implement screening programmes and to provide care 
and ongoing support to children with birth defects and 
their families’.2 Prevention is paramount; however, this 
is not yet possible for many congenital anomalies and 
hence a focus on improving postnatal care and outcomes 
is vital. The Sustainable Development Goal 3.2 aims to 
end preventable deaths of newborns and children under 
the age of 5 years by 2030.6 15 16 With one-third of infant 
deaths being attributed to congenital anomalies, clearly, 
this will not be achievable without an accelerated effort 
towards the provision of surgical care for children. It is 
estimated that two-thirds of deaths and disability from 
congenital anomalies can be avoided with the provision 
of neonatal and paediatric surgical care.6 Indeed, studies 
have demonstrated such provision can be highly cost-ef-
fective in terms of disability-adjusted life-years saved.5 
Yet, neonatal and paediatric surgical care remains a low 
priority on the global health agenda.5
A shift is needed to focus on the provision of surgical 
care for children within National Health Plans and 
International Organisations and to elevate congenital 
anomalies on the global health agenda. This large-scale, 
geographically comprehensive, multicentre prospective 
cohort study aims to define the current management and 
outcomes of a selection of common congenital anomalies 
globally and identify factors affecting outcomes that can 
be modified to improve care. This is vital to aid advocacy 
and global health prioritisation and inform future inter-
ventional studies aimed at improving outcomes.
AIM
To undertake the first large-scale, geographically compre-
hensive multicentre, prospective cohort study comparing 
the management and outcomes of a selection of common 
congenital anomalies in low, middle and high income 
countries across the globe.
oBjECTIvES
1. To compare the mortality and post-intervention com-
plications of a selection of common congenital anom-
alies involving the gastrointestinal tract in LMICs and 
HICs globally.
2. To identify patient-level and hospital-level factors af-
fecting outcomes that be modified to improve care.
3. To establish a research collaboration consisting of chil-
dren’s surgical care providers across the world to help 
enhance research capacity and to create a platform for 
ongoing collaborative research and intervention stud-
ies aimed at improving outcomes.
4. To raise awareness and provide advocacy for neonatal 
and paediatric surgical care within global health prior-
itisation, planning, policy and funding.
METhodS And AnAlySIS
Study design
This is an international, multicentre, prospective obser-
vational cohort study. The Global PaedSurg Research 
Collaboration consisting of children’s surgical care 
providers (collaborators) across the world was established 
from November 2017 to co-ordinate the study at an insti-
tutional level and facilitate data collection. Collaborators 
are free to choose one or more months between 1 October 
2018 to 30 April 2019 (inclusive) to recruit consecutive 
patients to the study, with a 30-day post-primary interven-
tion follow-up period. The primary intervention must 
occur within 30 days of presentation to be included in the 
study. Hence, the last date for primary data collection is 
29 June 2019. Following this, there will be a period of data 
collection for the data validation process continuing until 
the end of August 2019.
Collaborators
International collaborators will have a variety of roles 
and responsibilities within the study. Local collaborators 
Trust. Protected by copyright.
 o
n
 January 29, 2020 at G
uy's & St Thom
as' Hospitals NHS
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030452 on 3 September 2019. Downloaded from 
3Wright NJ. BMJ Open 2019;9:e030452. doi:10.1136/bmjopen-2019-030452
Open access
will establish mini-teams locally, gain study approval, use 
the protocol criteria to appropriately identify patients for 
study inclusion, collect prospective data and upload it to 
the Research Electronic Data Capture (REDCap) online 
system. Each hospital will have a local study lead who will 
hold overall responsibility for ensuring the data are accu-
rate, complete and without duplications. Country-lead 
collaborators will help to recruit other collaborators from 
within their country and provide advice and support 
regarding gaining local study approval and data collection. 
They may also help with translation of the study literature 
to the local language, if required. Continent and regional 
leads will help to recruit country leads, provide them with 
advice regarding the study and also encourage and co-ordi-
nate presentations of the protocol at national and interna-
tional meetings. Lead investigators contributed to the study 
design through the provision of feedback from the pilot 
studies undertaken in multiple languages. An organising 
committee will help to co-ordinate all study activities and a 
steering committee will provide guidance throughout.
There are a number of benefits for collaborators partic-
ipating in the study. Publishing journal(s) will be asked to 
make all collaborators PubMed-citable co-authors. This 
is based on an equal partnership model described by the 
Lancet and is used by a number of national and interna-
tional collaboratives.17–21 All collaborators will be listed as 
an author on resulting presentations. Collaborators will 
have the opportunity to present the study locally, nationally 
and internationally, initially the study protocol and later the 
results. This often provides collaborators, especially those 
who are junior or from LMICs, the opportunity to apply for 
funding to attend, present and network at such meetings. 
Participation in the study provides an easy route and insight 
into clinical research, which can be further established 
through participation in the 2-year Research Training 
Fellowship that is running alongside the main study free of 
charge for all interested collaborators.
Sample selection
Collaborator and hospital inclusion criteria
All hospitals and healthcare professionals providing 
surgical care for neonates and children, presenting for 
the first time, with one or more of the study conditions 
can be included in the study. Collaborators should gain 
permission from the senior surgeon or physician who 
oversees the care of the children to be included in the 
study in order to participate. There can be up to three 
collaborators in a mini-team per month of data collec-
tion. One mini-team can collect data over one or more 
months or several mini-teams can collect data over a 
different month each. Each mini-team must contain at 
least one senior surgeon or physician to oversee the data 
collection process.
Patient inclusion and exclusion criteria
Any neonate, infant or child under the age of 16 years, 
presenting acutely for the first time, with one or more 
of the study conditions can be included in the study. 
Patients who have previously received surgery for their 
presenting condition or those representing with a 
complication of surgery are excluded. Patients presenting 
electively for surgery are excluded. Children who have 
received basic resuscitative care for their condition at a 
different healthcare facility and are then transferred to 
the study centre for their primary surgical intervention 
can be included. Children who only receive resuscitative 
treatment at the study centre and are then referred else-
where for their primary surgical intervention cannot be 
included since the outcome of the surgical care will not 
be known and also to avoid the risk of duplicate patients 
in the study. Patients who receive conservative treatment 
as their primary intervention, palliative care or no care 
must be included within the study to accurately reflect the 
management and outcomes of all presenting cases.
If a patient presents with more than one of the study 
conditions, the details of each condition that they present 
acutely with can be included, but not a previously managed 
condition. For example, a newborn presenting with 
oesophageal atresia and anorectal malformation would 
have both conditions included. A patient presenting 
for the first time with Hirschsprung’s disease at several 
months of age who had a duodenal atresia repaired at 
birth would have the full details of the Hirschsprungs 
disease included, but the duodenal atresia would simply 
be noted as an associated anomaly.
outcome measures
The primary outcome is all-cause, in-hospital mortality.
For patient’s hospitalised for >30 days following primary 
intervention, a 30-day post-primary intervention mortality 
rate will be used. Those who do not receive a primary 
intervention, but remain alive and hospitalised at 30 days 
following primary admission, will have this time point 
used for recording their mortality status for the primary 
outcome. Primary outcome is defined in table 1.
The secondary outcomes include complications occur-
ring within 30 days of primary intervention:
 ► Surgical-site infection.
 ► Wound dehiscence.
 ► Need for re-intervention.
 ► Condition-specific complications.
 ► Condition specific outcome variables.
 ► Length of hospital stay or time from admission to 
death in patients who do not survive.
 ► 30-day post-primary intervention mortality.
Secondary outcomes will not be collected on patients 
who do not receive a primary intervention within 30 days 
of hospital admission, with the exception of length 
of hospital stay or time from admission to death. Thir-
ty-day follow-up will be undertaken within the capacity 
of the collaborating team; no additional funding will be 
provided.
data collection
Generic variables relating to the patient demographics, 
antenatal care, prehospital care, clinical condition, surgical 
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Table 1 Generic data points
Generic questions Answers
During which month did the patient 
present to your hospital?
October, November, December, January, February, March, April.
Please select the month that the patient presented to your hospital for the first time with this congenital 
anomaly. For example, if a baby was born with gastroschisis on the 29 September and presented to 
your hospital on 1 October you should select October.
Has consent been provided to include 
this patient in the study?
If no, which condition did the patient 
present with?
Yes, No, Patient consent is not required for this study at my institution.
 
Oesophageal atresia, Congenital diaphragmatic hernia, Intestinal atresia, Gastroschisis, Exomphalos, 
Omphalocele, Anorectal malformation, Hirschsprung's Disease.
Please select all the conditions that the patient presented with. Do not select a condition which the 
patient has already received surgical treatment for previously.
Demographics
Gestational age at birth Number of weeks from the first day of the women's last menstrual cycle until birth. Round up or down 
to the nearest week.
Age at presentation (in hours) We understand this information may be difficult to obtain - please be as accurate as you can. Please 
round to the nearest hour. This number may be very large for patients who have a delayed presentation 
- please still enter it. For neonates born within your centre please enter 0. Enter unknown if unknown.
Gender Male, Female, Ambiguous, Unknown.
Weight at presentation In kilograms (kg) on the day of presentation. Please provide a value to one decimal place.
Does the patient have another 
anomaly in addition to the study 
condition?
Yes: Cardiovascular, Yes: Respiratory, Yes: Gastrointestinal, Yes: Neurological, Yes: Genito-urinary, Yes: 
Musculoskeletal, Yes: Down syndrome, Yes: Beckwith-Wiedemann syndrome, Yes: Cystic fibrosis, Yes: 
Chromosomal, Yes: Other, No.
Select all that apply. Include all anomalies diagnosed at any stage up until 30 days post-primary 
intervention or 30 days following presentation for those who did not receive an intervention. If you 
suspect an associated anomaly, but it has yet to be diagnosed, select 'Yes: Other'.
Distance from the patient's home to 
your hospital
In kilometres (km). Please round to the nearest kilometre. Please enter 0 if born in your hospital.
Antenatal care and delivery
Antenatal ultrasound undertaken?
If the condition was diagnosed 
antenatally, at what gestational age?
Yes: study condition diagnosed, Yes: problem identified but study condition not diagnosed, Yes: no 
problem identified, No.
 
Please round up to the nearest week. If the patient has more than one study condition, please note the 
gestational age at which one or more of the conditions was first diagnosed.
Mode of transport to hospital?
Where did the patient present from? If 
other, please specify.
Ambulance, Other transport provided by the health service, Patient's own transport, Born within the 
hospital.
Home, Community Clinic, General Practice, District Hospital, Other, Unknown.
District hospital includes secondary-level healthcare, provincial hospital, general hospital, general 
mission hospital or regional hospital. It has general anaesthesia and can provide general surgical care.
Type of delivery: Vaginal (spontaneous), Vaginal (induced), Caesarean section (elective), Caesarean section (urgent/non-
elective), Unknown. Vaginal delivery includes those requiring forceps and ventouse.
Clinical condition and patient care
Was the patient septic on arrival?
 
If yes, were appropriate antibiotics 
administered?
Yes, no.
Sepsis is SIRS with a suspected or confirmed bacterial, viral or fungal cause. SIRS is a response to a 
stimulus, which results in two or more of the following: temperature >38.5°C or <36°C, tachycardia*, 
bradycardia* in children <1 year old, tachypnoea*, leucopenia or leucocytosis*, hyperglycaemia*, altered 
mental status, hyperlactaemia*, increased central capillary refill time >2 seconds. Arrival is the time of 
birth for neonates born at your hospital. *Variables are defined as values outside the normal range for 
age.
Yes: within 1 hour of arrival, Yes: within the first day of arrival, No.
Appropriate antibiotics are defined as either broad spectrum covering gram negative, gram positive and 
anaerobic bacteria OR antibiotics that are the standard empirical treatment for that condition according 
to local guidelines OR are based on sensitivities provided by a microbiology sample.
Continued
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Generic questions Answers
Was the patient hypovolaemic on 
arrival?
If yes, was an intravenous fluid bolus 
given?
If yes, how much intravenous fluid 
was given?
Yes, No. Criteria for diagnosis include at least one of the following: prolonged central capillary refill 
time >2 seconds, *tachycardia, mottled skin, *reduced urine output, cyanosis, impaired consciousness, 
*hypotension. *Variables are defined as values outside the normal range for age.
Yes: within 1 hour of arrival, Yes: on the first day of arrival, No.
 
10–20 mL/kg, >20 mL/kg.
If <10 mL/kg was given, please select 'no' for the question asking if intravenous fluid was given.
Was the patient hypothermic on 
arrival?
If yes, was the patient warmed on 
arrival to within a normal temperature 
range?
Yes, No. Defined as <36.5°C core temperature. Arrival is the time of birth for neonates born at your 
hospital.
 
Yes, No. Only select yes if warming was commenced within 1 hour of arrival. Arrival is the time of birth 
for neonates born at your hospital.
Did the patient receive central venous 
access?
If yes, did the patient acquire central 
line sepsis?
Yes: umbilical catheter, Yes: peripherally inserted central catheter, Yes: percutaneously inserted central 
line with ultrasound guidance, Yes: surgically placed central line (open insertion), No.
Please select all that the patient received within 30 days of primary intervention or 30 days of 
presentation if no intervention was undertaken.
Yes: diagnosed clinically, Yes: confirmed on microbiology, No.
Within 30 days of primary intervention or 30 days of presentation if no intervention was undertaken.
Time from arrival at your hospital to 
primary intervention in hours
Enter 0 if no intervention was undertaken.
Primary intervention for each condition is defined as follows. Oesophageal atresia: surgery, either 
temporising or definitive, to manage the oesophageal atresia and/or tracheo-oesophageal fistula. 
Congenital diaphragmatic hernia: surgery to reduce the hernia and close the defect. Intestinal atresia: 
surgery, either temporising or definitive, to manage the obstruction including stoma formation and 
primary anastomosis. Gastroschisis: any procedure to either cover or reduce the bowel and/or close the 
defect. This includes application of a silo (regardless of whether or not they go on to require surgery). 
It excludes initial covering of the bowel in a plastic covering (bag or cling film) prior to intervention. 
Exomphalos: surgery or application of topical treatment to the sac in patients managed conservatively 
(regardless of whether or not they go on to require surgery). Hirschsprung's disease: surgery, either 
temporising or definitive, or rectal/distal bowel irrigation, laxatives or digital stimulation in patients 
managed conservatively. This does not include pre-operative washouts in patients planned to have 
surgery. Anorectal malformation: surgery, either temporising or definitive, or anal/fistula dilatation in 
patients with a low anorectal malformation managed conservatively.
American Society of 
Anesthesiologists Score at the time of 
primary intervention
1.Healthy person, 2. Mild systemic disease, 3. Severe systemic disease, 4. Severe systemic disease 
that is a constant threat to life, 5. A moribund patient who is not expected to survive without the 
operation, Not applicable — no intervention.
What type of anaesthesia was used 
for the primary intervention?
General anaesthesia with endotracheal tube, General anaesthesia with laryngeal airway, Ketamine 
anaesthesia, Spinal/caudal anaesthesia, Local anaesthesia only, No anaesthesia/just analgesia, No 
anaesthesia/no analgesia, Not applicable: no surgery or intervention undertaken.
Who undertook the anaesthetic for 
the primary intervention?
Anaesthetic doctor, Anaesthetic nurse, Medical officer, Surgeon, Other healthcare professional, No 
anaesthetic undertaken.
If more than one of these personnel were present, please select the most senior.
Who undertook the primary 
intervention?
Paediatric surgeon (or junior with paediatric surgeon assisting/in the room), General surgeon (or 
junior with paediatric surgeon assisting/in the room), Junior doctor, medical officer or other (without a 
paediatric or general surgeon assisting/in the room), Trainee surgeon (without a paediatric or general 
surgeon assisting or in the room), Not applicable — no surgery or primary intervention undertaken.
Was a Surgical Safety Checklist used 
at the time of primary intervention?
Yes, No: but it was available, No: it was not available, Not applicable: a conservative primary 
intervention was undertaken, Not applicable: no surgery or primary intervention undertaken.
Total duration of antibiotics following 
primary intervention
In days (including the day of surgery and the day antibiotics were stopped. Include intravenous and oral 
antibiotics).
Did the patient receive a blood 
transfusion?
Yes: not cross-matched, Yes: cross-matched, No: not required, No: it was required but not available.
Within 30 days of primary intervention or 30 days of presentation if no intervention was undertaken.
Did the patient require ventilation?
If yes, for how long did the patient 
remain on ventilation?
Yes: and it was given, Yes: but it was not available, No.
Within 30 days of primary intervention or 30 days of presentation if no intervention was undertaken. 
Please include all types of ventilation.
 
In days (include all days on ventilation within 30 days of primary intervention or 30 days of presentation 
if no intervention was undertaken).
Table 1 Continued
Continued
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Generic questions Answers
Time to first enteral feed (post-
primary intervention)
In days (include the day of primary intervention and the day of first enteral feed in the calculation). Enter 
0 if enteral feeds were not commenced. Enter 999 if feeds were not stopped, for example, in patients 
with Hirschsprung's Disease managed conservatively. Include all types of enteral feeding — oral, 
nasogastric, gastrostomy and other.
Time to full enteral feeds (post-
primary intervention)
In days (enter 0 if the patient died before reaching full enteral feeds or 30 if the patient had not reached 
full enteral feeds at 30 days post-primary intervention or 30 days following admission in patients 
who did not receive a primary intervention). Include all types of enteral feeding — oral, nasogastric, 
gastrostomy and other.
Did the patient require parenteral 
nutrition?
If yes, for how long did the patient 
receive parenteral nutrition?
Yes and it was given, Yes and it was sometimes available but less than required, Yes but it was not 
available, No.
 
In days. Include all days that the patient received parenteral nutrition (any volume) up until 30 days post-
primary intervention or 30 days following presentation in patients who do not receive an intervention.
Outcomes
Did the patient survive to discharge?
If the patient was discharged prior, 
were they still alive at 30 days 
following primary intervention?
If no, cause of death?
Yes, No.
Select yes if the patient was still alive in your hospital 30 days after primary intervention or 30 days after 
presentation in patients who did not receive a primary intervention.
 
Yes, No: not followed-up after discharge, Followed-up but not until 30 days post-primary intervention.
This can include all reliable communication with the patient/patient’s family including in person, via 
telephone and other.
 
Sepsis, aspiration pneumonia, respiratory failure, cardiac failure, malnutrition, electrolyte disturbance, 
haemorrhage, lack of intravenous access, hypoglycaemia, recurrent tracheo-oesophageal fistula, 
recurrent diaphragmatic hernia, anastomotic leak, ischaemic bowel, ruptured exomphalos sac, 
enterocolitis, other. If other, please specify.
Duration of hospital stay (days) Please include the day of admission and the day of discharge in your calculation. For example, if a 
patient presented on 1 October and was discharged on the 5 October, their duration of hospital stay 
would be 5 days. If the patient died, please record the number of days from admission to death. Only 
include the duration of the primary admission, not subsequent admissions if the patient re-presented.
Did the patient have a surgical site 
infection?
Yes, No, Not applicable: no surgical wound.
This is defined as one or more of the following within 30 days of surgery: (1) purulent drainage from the 
superficial or deep (fascia or muscle) incision, but not within the organ/space component of the surgical 
site OR (2) at least two of: pain or tenderness, localised swelling, redness, heat, fever, AND the incision 
is opened deliberately to manage infection, spontaneously dehisces or the clinician diagnoses an SSI 
(negative culture swab excludes this criterion) OR (3) there is an abscess within the wound (clinically or 
radiologically detected).
Did the patient have a full thickness 
wound dehiscence?
Yes, No, Not applicable — no surgical wound.
This is defined as all layers of the wound opening within 30 days of surgery.
Did the patient require a further 
unplanned intervention?
Yes — percutaneous intervention, Yes — surgical intervention, No, Not applicable — no primary 
intervention undertaken.
Within 30 days of primary intervention. This does not include routine reduction and closure of the defect 
in neonates with gastroschisis receiving a preformed silo.
Was the patient followed up at 
30 days post primary surgery 
or intervention to assess for 
complications?
Yes: reviewed in person, Yes: via telephone consultation, Yes: via other means, Yes: still an in-patient 
at 30 days, No: data are based on in-patient observations only, No: follow-up was done but prior to 
30 days.
If the patient had a complication, 
when was it diagnosed?
During the primary admission, As an emergency re-attender, At routine follow-up as an outpatient, Not 
applicable: no complications.
What study condition does this 
patient have?
Oesophageal atresia, Congenital diaphragmatic hernia, Intestinal atresia, Gastroschisis, Exomphalos/
Omphalocele, Anorectal malformation, Hirschsprung's Disease.
If the patient has presented for the first time with more than one of these conditions, please select all 
that apply. If the patient presented on this occasion with one of these conditions, but previously had 
another condition managed then only select the condition they are presenting with on this occasion and 
enter that they have another anomaly in the demographics section above. For example, if the patient 
presents at 2 months with Hirschsprung's disease, but previously had a duodenal atresia repair, please 
select Hirschsprung's disease here (not intestinal atresia) and tick in the section above that they have 
another gastrointestinal anomaly.
SIRS, Systemic Inflammatory Response Syndrome.
Table 1 Continued
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intervention and outcomes will be collected for all patients 
in the study (table 1). Specific variables will be collected for 
each individual condition (online supplementary file 1).
Outcomes and variables have been chosen using 
published core outcome sets and commonly collected 
outcomes in systematic reviews and meta-analyses.22–37 
Collaborators will enter anonymous, deidentified data 
via the secure internet-based REDCap system. This will be 
stored on King’s College London REDCap server.
A short survey will be completed by the local study lead 
and one other collaborating consultant or registrar on the 
resources and facilities available for neonatal and paediatric 
surgical care at their centre (online supplementary file 2).
data quality
To ensure high quality of data, a detailed protocol for 
collaborators has been produced and published on the 
study website ( www. globalpaedsurg. com) in 12 languages: 
English, French, Spanish, Portuguese, German, Italian, 
Chinese, Arabic, Korean, Lithuanian, Turkish and 
Russian. Clear and concise definitions have been provided 
for all data points on the protocol, on the data collec-
tion forms and within REDCap when entering the data. 
A study launch meeting was undertaken where the prin-
cipal investigator presented the data collection process 
in detail, demonstrated use of REDCap and answered 
questions. This was recorded, circulated to all collabo-
rators via email and placed on the website. A frequently 
asked questions document has been circulated via email 
and placed on the website. Two meetings were held by 
the principal investigator to detail the study, data collec-
tion process and answer questions among the country 
leads so they in turn can provide advice and support to 
local collaborators within their country. Again this was 
recorded, circulated and placed on the website.
A pilot study of the patient data collection form and 
institutional survey was undertaken by lead investigators 
to optimise the study design and to address any feasibility 
or other barriers to effective data collection and study 
completion across participating sites. The pilot study 
commenced on 1 August 2018 for 30 days in English, 
Spanish and French by 41 collaborator colleagues. The 
data collection forms were amended following feedback 
to clarify terminology, add important missing variables or 
descriptions and correct any translation errors. All trans-
lated data collection forms, REDCap and study documen-
tation have been checked and verified by a native speaker 
for accuracy.
data validation
Ten percent of collaborating centres will be selected at 
random for data validation by an independent research 
collaborator. The aim will be to determine the numbers 
of patients eligible during the data collection period to 
check if any were missed and collect a selection of data 
again to cross-check for accuracy. Validating questions 
have been built into the data collection tool. At least 90% 
of primary and secondary outcomes must be completed 
for each patient. All collaborators within validating 
centres will be asked to complete a brief survey regarding 
their experience with data collection to identify any 
potential errors and to aid with data interpretation.
Sample size calculation
A sample size calculation was undertaken using Stata/
IC V.15.0 based on Bonferroni correction for multiple 
testing, assuming 80% power and an overall type 1 error 
of 5%. The required sample size for each condition has 
been calculated for the primary outcome of mortality in 
LMICs compared with HICs and also low, middle and 
high income countries separately (table 2). Mortality esti-
mations are based on pooled data from published studies 
on these conditions in low, middle and high income 
countries, respectively.
Based on the patient numbers included in the previ-
ously undertaken PaedSurg Africa study, which used a 
similar study design, the estimated sample sizes to detect 
a significant difference between LMICs and HICs in this 
study are achievable.11
Estimated study population
The mean number of cases presenting to an institution 
per month for each study condition was estimated from 
published studies across all income settings (table 2). On 
average, most institutions caring for patients with these 
conditions receive 1–2 new cases per month; each partic-
ipating institution would expect approximately 7–14 new 
cases in the study per month although this can vary. The 
aim is to include a minimum of 365 months of data; 183 
months from LMICs and 183 months from HICs. This 
should ensure enough cases of exomphalos to determine 
a significant difference between LMICs and HICs; fewer 
months of data are required to determine significant 
differences between other study conditions. An up-to-
date total of patient numbers within the study will be 
maintained on the study website.
data analysis
Patient and institutional data
Data will be analysed using Stata and SAS V.9.4 (Cary, 
North Carolina, USA). Missing data for the covari-
ates will be analysed to determine whether it is related 
to the outcome and either complete-case analyses or 
multiple imputation techniques will be used for analyses 
accordingly.
Significant differences in mortality between LMICs and 
HICs will be determined for each of the study conditions 
using Χ2 analysis, or Fischer’s exact test if either group 
contains <10 patients. World Bank classification of low, 
middle and high income countries during the fiscal year 
2018 will be used.38
Univariate logistic regression analyses will be conducted 
between covariates and the primary outcome of mortality. 
Based on the results, covariates with a p value <0.10 will 
be included in the multivariate model. The final multi-
level multivariate logistic model will be determined using 
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Table 2 Estimated mortality and sample sizes for low, middle and high income countries and the mean number of cases per 
month per institution globally
Condition
Mortality LIC
(%, n)
Mortality 
MIC
(%, n)
Mortality 
LMIC 
combined
(%, n)
Mortality HIC
(%, n)
Sample size 
for LIC
Sample 
size for 
MIC
Sample 
size for 
HIC
Sample 
size for 
LMIC vs 
HIC (per 
group)
Mean no. 
cases/ 
month/ 
institution (L, 
M and HIC 
combined)
OA ±TOF 79.5%
(62/78)
41.8%
(623/1488)
43.7%
(685/1566)
2.7%
(6/221)
34 34 23 21 1.02
CDH – 47.4%
(130/274)
47.4%
(130/274)
20.4%
(201/982)
– – – 63 0.54
IA 42.9%
(42/98)
40.0%
(97/241)
41.0%
(139/339)
2.9%
(12/407)
6014 6014 25 24 0.63
Gastroschisis 83.1%
(211/254)
42.6%
(205/481)
56.6%
(416/735)
3.7%
(28/748)
29 29 24 15 0.85
Exomphalos 25.5% 
(41/161)
31.9% 
(132/414)
30.1% 
(173/575)
12.7% 
(40/316)
1040 1040 196 115 0.63
ARM 26.3%
(26/99)
17.5%
(243/1391)
18.1%
(269/1490)
3%
(14/462)
460 460 90 85 1.34
Hirschsprung’s 
disease
19.1% 
(33/173)
16.8% 
(55/328)
17.6%
(88/501)
2.3%
(43/1897)
5802 5802 85 79 2.21
ARM, anorectal malformation; CDH, congenital diaphragmatic hernia; HIC, high income countries; IA, intestinal atresia; LIC, low income countries; 
LMIC, low and middle income countries; MIC, middle income countries; OA, oesophageal atresia; TOF, tracheo-oesophageal fistula.
stepwise backward elimination to interventions and 
peri-operative factors affecting outcomes. Data will be 
adjusted for confounding factors and effect modifiers. 
Potential confounders include gestation age at birth, 
weight, time from birth to presentation and American 
Society of Anesthesiologists score at the time of primary 
intervention. Potential effect modifiers include adminis-
tration of peri-operative antibiotics, fluid resuscitation, 
thermal control and provision of other condition-specific 
neonatal care such as parenteral nutrition in neonates 
with gastroschisis.
Multi-level multivariate logistic regression analysis 
will also be undertaken to identify institutional factors 
affecting mortality with adjustment for confounders. 
P<0.05 will be deemed significant.
Data validation
A weighted kappa statistic will be used to determine the 
level of agreement between the patient data in the main 
study and the validation data. It will also be used to deter-
mine the level of agreement between institutional surveys 
independently completed by the local study lead and one 
other consultant or registrar at each participating centre. 
Results will be presented as a proportion of agreement 
for each variable being validated.
Patient and public involvement
CDH UK, a patient and family advisory group and charity, 
provided input into the design of the study protocol and 
data collection tool. Their input will be sought on the 
findings and dissemination of the results.
EThICS And dISSEMInATIon
Research ethics approval
The study has been classified as an audit at the host 
institution and hence did not require ethical approval. 
The study fulfils the audit criteria as follows: (1) All data 
collected measures current practice. The study does not 
involve any changes to patient management. (2) Current 
practice and outcomes in low, middle and high income 
countries will be compared with published standards 
in the literature. Table 2 details the current mortality 
standards for each of the seven study conditions in high 
income countries. (3) All the study data are routinely 
collected information which should be known to the 
study team without asking additional questions to the 
patients/parents. (4) All data to be entered into REDCap 
are entirely anonymous. (5) No individual patient, 
collaborator, institution or country will be independently 
identifiable in the study results. (6) All data will be stored 
securely and will be governed by King’s College London 
data protection team.
Research collaborators were required to gain approval 
to participate in the study at their institution according to 
their local ethical regulations. Data transfer agreements 
were legally signed between institutions where required. 
The participating institutions, type of study approval 
and study approval reference numbers are detailed in 
online supplementary file 3. It was not mandated for 
study approvals to be translated into English. Hence, 
some reference numbers are in the local scripture of the 
participating country and have therefore not been incor-
porated into the table.
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Study dissemination
The study concept and design will be presented at inter-
national conferences in order to recruit collaborators. 
Following completion, the results will be presented at 
local, national and international conferences globally. 
Both the promotional presentations of the study protocol 
and the study results will be presented by study collabo-
rators of all levels of training, disciplines and regions of 
the world. The results will be submitted for open access 
publication in a peer reviewed journal. Following publi-
cation, the full anonymous, deidentified dataset will be 
made publicly available via an online repository. Collabo-
rators will have the opportunity to undertake sub-analyses 
of the data for their country (if all collaborators from that 
country agree), region or continent.
dISCuSSIon
This study aims to define, for the first time, the manage-
ment and outcomes of a selection of common life-threat-
ening congenital anomalies across the globe. This will 
help to raise awareness of the unacceptable disparities 
in outcomes between low, middle and high income 
countries and the need to focus on improving access to 
quality surgical care for neonates with congenital anom-
alies within national health plans and global health 
prioritisation. It is hoped that factors affecting mortality 
and morbidity will be identified that can be modified 
to improve care. Establishment of the Global PaedSurg 
Research Collaboration developed during this study will 
create a platform for ongoing collaborative work and 
interventional studies aimed at improving outcomes in 
the future.
Twitter @GlobalPaedSurg
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